News Vertex hit by phase 3 cystic fibrosis failure Company looks to other CF sub-groups to yield success
News Vertex seeks deal after NICE rejects CF drug Orkambi Company in talks with NICE over patient access scheme.
News Biogen signs $1bn gene therapy deal; CF trial shows promise Biogen following move into regenerative medicine
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
